Anemia due to coadministration of Renin-Angiotensin-System inhibitors and PPARγ agonists in uncomplicated diabetic patients

Experimental and Clinical Endocrinology and Diabetes

Volumn 120, Issue 7, 2012, Pages 416-419

  Raptis, A E ^a   Bacharaki, D ^a   Mazioti, M ^a   Marathias, K P ^b   Markakis, K P ^a   Raptis, S A ^a,c   Dimitriadis, G D ^a   Vlahakos, D V ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

^c Prevention and Treatment of Diabetes Mellitus and Its Complications   (Greece)

Author keywords

cardiovascular incidences; diabetes; hypertension

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;

ADULT; ANEMIA; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL SIGNIFICANCE;

AGED; ANEMIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMATOCRIT; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PPAR GAMMA; RENIN-ANGIOTENSIN SYSTEM; THIAZOLES;

EID: 84863781837     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0032-1306286     Document Type: Article

References (31)

1. American Hospital Formulary Service Drug Information 1988. Bethesda American Society of Health-System Pharmacists: 1988; 906
2. Aso Y, Suganuma R, Wakabayashi S et al. Anemia is associated with an elevated serum level of high-molecular-weight adiponectin in patients with type 2 diabetes independently of renal dysfunction. Transl Res: 2009; 154 175 182
3. Bermudez V, Finol F, Parra N et al. PPAR-gamma agonists and their role in type 2 diabetes mellitus management. Am J Ther: 2010; 17 274 283
4. Berria R, Gastaldelli A, Lucidi S et al. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clin Pharmacol Ther: 2006; 80 105 114 (Pubitemid 44164408)
5. Berria R, Glass L, Mahankali A et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin Pharmacol Ther: 2007; 82 275 281 (Pubitemid 47260544)
6. Bhatia V, Chaudhuri A, Tomar R et al. Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care: 2006; 29 2289 2294 (Pubitemid 44899867)
7. El-Achkar T M, Ohmit S E, McCullough P A et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency. The Kidney Early Evaluation Program Kidney International: 2005; 67 1483 1488 (Pubitemid 40463125)
8. Gossmann J, Burkhardt R, Harder S et al. Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney Int: 2001; 60 83 86 (Pubitemid 32587542)
9. Hirakata H, Onoyama K, Iseki K et al. Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol: 1984; 4 355 360 (Pubitemid 15189808)
10. Hirase N, Yanase T, Mu Y et al. Thiazolidinedione suppresses the expression of erythroid phenotype in erythroleukemia cell line K562. Leuk Res: 2000; 24 393 400 (Pubitemid 30227239)
11. Hollenberg N K. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med: 2003; 115 111
12. Iodice C, Balletta M M, Minutolo R et al. Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis. Kidney Int: 2003; 63 2214 2221 (Pubitemid 36605834)
13. Ishani A, Weinhandl E, Zhao Z et al. Angiotensin converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol: 2005; 45 391 399 (Pubitemid 40186790)
14. Jacobsen P, Andersen S, Jensen B R et al. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol: 2003; 14 992 999 (Pubitemid 36359280)
15. Karalliedde J, Buckingham R E. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf: 2007; 30 741 753 (Pubitemid 47347350)
16. Kim M K, Baek K H, Lim D J et al. Erythropoietin response to anemia and its association with autonomic neuropathy in type 2 diabetic patients without advanced renal failure. J Diabetes Complications: 2010; 24 90 95
17. Kuriyama S, Tomonari H, Tokudome G et al. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res: 2002; 25 849 855 (Pubitemid 36024640)
18. Laverman G D, Remuzzi G, Ruggenenti P. ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? J Am Soc Nephrol: 2004; 15 64 70
19. Mrug M, Stopka T, Julian B A et al. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest: 1997; 100 2310 2314 (Pubitemid 27500154)
20. Nesto R W, Bell D, Bonow R O et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Circulation: 2003; 108 2941 2948 (Pubitemid 37517824)
21. Neusschwander-Tetri B A, Brunt E M, Wehmeier K P et al. Interim results of a pilot study demonstrationg the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol: 2003; 38 434 440 (Pubitemid 36399245)
22. Plata R, Cornejo A, Arratia C et al. Angiotensin converting-enzyme inhibition therapy in altitude polycythaemia:a prospective randomised trial. Lancet: 2002; 359 663 666 (Pubitemid 34203766)
23. Rothwell C, McGuire E J, Altrogge D M et al. Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci: 2002; 27 35 47 (Pubitemid 34296681)
24. Scheen A J. Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf: 2004; 27 841 856 (Pubitemid 39331683)
25. Thomas M C. The high prevalence of anemia in diabetes is linked to functional erythropoietin deficiency. Semin Nephrol: 2006; 26 275 282 (Pubitemid 44754687)
26. Vlahakos D V, Canzanello V J, Madaio M P et al. Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis: 1991; 17 199 205
27. Vlahakos D V, Marathias K P, Agroyannis B et al. Posttransplant erythrocytosis. Kidney Int: 2003; 63 1187 1194 (Pubitemid 36349983)
28. Vlahakos D V, Marathias K P, Kosmas E N. Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis. Ann Intern Med: 2001; 134 426 427 (Pubitemid 32179484)
29. Vlahakos D V, Marathias K P, Madias N E. The Role of the Renin-Angiotensin System in the Regulation of Erythropoiesis. Am J Kidney Dis: 2010; 56 558 565
30. Von Eynatten M, Baumann M, Heemann U et al. Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest: 2010; 40 95 102
31. Wolf G, Müller N, Hunger-Battefeld W et al. Hemoglobin concentrations are closely linked to renal function in patients with type 1 or 2 diabetes mellitus. Kidney Blood Press Res: 2008; 31 313 321